Case number 2018-2273
Argentum Pharmaceuticals LLC v. Novartis Pharmaceuticals Corp. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | ARGENTUM PHARMACEUTICALS LLC v. NOVARTIS PHARMACEUTICALS CORP. [OPINION] [precedential] (0) |
| Mar 22, 2021 | 25 | The petition for writ of certiorari, No. 20-779, filed on 12/04/2020, was Denied on 03/22/2021. [764281] [JCP] [Entered: 03/23/2021 03:44 PM] (0) |
| Dec 10, 2020 | 24 | Petition for writ of certiorari filed on 12/04/2020, and placed on the docket 12/08/2020, in the U.S. Supreme Court. No.: 20-779, Argentum Pharmaceuticals LLC v. Novartis Pharmaceuticals Corporation. [741779] [JAB] [Entered: 12/10/2020 11:11 AM] (0) |
| Jul 16, 2020 | 23 | Mandate issued to the United States Patent and Trademark Office. Service as of this date by the Clerk of Court. [707936] [JAB] [Entered: 07/16/2020 09:39 AM] (0) |
| Jul 9, 2020 | 22 | ORDER filed denying [20] petition for en banc rehearing filed by Argentum Pharmaceuticals LLC. By: En Banc (Per Curiam). Service as of this date by the Clerk of Court. [706380] [JAB] [Entered: 07/09/2020 12:52 PM] (0) |
| Jun 29, 2020 | 21 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellant Argentum Pharmaceuticals LLC. Service: 06/29/2020 by email. [704326] [18-2273] [Teresa Rea] [Entered: 06/29/2020 01:17 PM] (0) |
| Jun 8, 2020 | 19 | Entry of appearance for Ali H.K. Tehrani as of counsel for Appellant Argentum Pharmaceuticals LLC. Service: 06/08/2020 by email. [699839] [18-2273] [Ali Tehrani] [Entered: 06/08/2020 02:17 PM] (0) |
| Jun 8, 2020 | 20 | Petition for en banc rehearing filed by Appellant Argentum Pharmaceuticals LLC. Service: 06/08/2020 by email. [699845] [18-2273] [Teresa Rea] [Entered: 06/08/2020 02:23 PM] (0) |
| Jun 1, 2020 | 18 | ORDER filed denying [17] motion to extend time to file petition for rehearing/en banc filed by Argentum Pharmaceuticals LLC. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [698282] [JAB] [Entered: 06/01/2020 02:14 PM] (0) |
| May 29, 2020 | 17 | MOTION of Appellant Argentum Pharmaceuticals LLC to extend the time to file a Petition for Rehearing En Banc until 06/29/2020 [Consent: opposed]. Service: 05/29/2020 by email. [697944] [18-2273] [Teresa Rea] [Entered: 05/29/2020 03:37 PM] (0) |
| May 1, 2020 | 16 | ORDER filed granting motion to extend time to file petition for rehearing/en banc [15] filed by Appellant Argentum Pharmaceuticals LLC. Petition for Rehearing due on or before 06/08/2020. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [691545] [JAB] [Entered: 05/01/2020 09:38 AM] (0) |
| Apr 30, 2020 | 15 | MOTION of Appellant Argentum Pharmaceuticals LLC to extend the time to file a Petition for Rehearing En Banc until 06/08/2020 [Consent: opposed]. Service: 04/30/2020 by email. [691336] [18-2273] [Teresa Rea] [Entered: 04/30/2020 02:39 PM] (6) |
| Apr 23, 2020 | 13 | OPINION filed for the court by Lourie, Circuit Judge; Moore, Circuit Judge and Reyna, Circuit Judge. Precedential Opinion. [689405] [JAB] [Entered: 04/23/2020 09:44 AM] (7) |
| Apr 23, 2020 | 14 | JUDGMENT. DISMISSED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [689407] [JAB] [Entered: 04/23/2020 09:45 AM] (1) |
| Feb 14, 2020 | 12 | Argentum's Opposition to Novartis' Suggestion of Mootness for Appellant Argentum Pharmaceuticals LLC. Service: 02/14/2020 by email. [671630] [18-2273] [Teresa Rea] [Entered: 02/14/2020 03:28 PM] (10) |
| Feb 12, 2020 | 10 | ORDER granting motion to dismiss appeal pursuant to FRAP 42(b) [669539-2] filed by Appellants Apotex Inc., Apotex Corp. and Appellee Novartis Pharmaceuticals Corporation. in 18-2209; issuing mandate in 18-2209; modifying the official caption in 18-2273. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [670725] [18-2209, 18-2273] [JAB] [Entered: 02/12/2020 12:49 PM] (2) |
| Feb 12, 2020 | 11 | NOTE TO FILE: FOR PRIOR ENTRIES SEE 18-2209. [670735] [JAB] [Entered: 02/12/2020 12:59 PM] (0) |
| Jan 16, 2019 | 9 | Corrected Certified list from the United States Patent and Trademark Office. Service: 01/09/2019 by email. [578417] [18-2209, 18-2230, 18-2260, 18-2273] [MMA] [Entered: 01/16/2019 09:28 AM] (227) |
| Oct 15, 2018 | 8 | Certified list from the United States Patent and Trademark Office. Service: 10/12/2018 by email. [557122] [TAM] [Entered: 10/15/2018 02:13 PM] (227) |
| Sep 5, 2018 | 7 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Filings for Appellee ([3], [4], [5], [6]) were made in 18-2273 which is a consolidated appeal. CORRECTION: Documents should only be filed in lead appeal 18-2209 (see entry [2]), unless otherwise directed by the court. These documents do not need to be refiled. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [547356] [CMP] [Entered: 09/05/2018 02:05 PM] (0) |
| Aug 29, 2018 | 3 | Entry of appearance for Jane M. Love, Ph.D. as principal counsel for Not party Novartis Pharmaceuticals Corporation and Appellee Novartis AG. Service: 08/29/2018 by email. [546016] [18-2273] [Jane Love] [Entered: 08/29/2018 10:21 AM] (3) |
| Aug 29, 2018 | 4 | Certificate of Interest for the Not party Novartis Pharmaceuticals Corporation and Appellee Novartis AG. Service: 08/29/2018 by email. [546019] [18-2273] [Jane Love] [Entered: 08/29/2018 10:22 AM] (3) |
| Aug 29, 2018 | 5 | Docketing Statement for the Appellee Novartis AG. Service: 08/29/2018 by email. [546023] [18-2273] [Jane Love] [Entered: 08/29/2018 10:24 AM] (4) |
| Aug 29, 2018 | 6 | Entry of appearance for Robert W. Trenchard as of counsel for Not party Novartis Pharmaceuticals Corporation and Appellee Novartis AG. Service: 08/29/2018 by email. [546024] [18-2273] [Robert Trenchard] [Entered: 08/29/2018 10:26 AM] (3) |
| Aug 20, 2018 | 1 | Appeal docketed. Received: 08/16/2018. [543948] Certified List due on 10/01/2018. [CMP] [Entered: 08/20/2018 10:30 AM] (65) |
| Aug 20, 2018 | 2 | Note to file: The following cases are associated: 18-2209 Lead with 18-2273 Consolidated. Argentum Pharmaceuticals LLC entry of appearance, certificate of interest, and docketing statement are due by 09/04/2018. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [543968] [18-2209, 18-2273] [CMP] [Entered: 08/20/2018 11:13 AM] (0) |
